BICO Group AB Class B · OMXSTO:BICO
BICO Group AB Class B — Q3 2026 Earnings Presentation
29 slides from BICO Group AB Class B's earnings presentation, Nov 11, 2026

Slide 1: Interim Report Q3 2026 Earnings Call
INTERIM REPORT Q3 2026 EARNINGS CALL – WEDNESDAY, NOVEMBER 11, 2026

Slide 2: Disclaimer
DISCLAIMER You must read the following before continuing. The fol- for publication, release or distribution in the United affect the extent to which a particular projection is real- lowing applies to this document and the information pro- States, the United Kingdom, Australia, Canada or Japan, ised.

Slide 3: Q3 2026 Earnings Call Agenda
Q3 2026 Earnings Call Agenda BICO 2030 Strategy Group Financial Performance Q3 2026 Focus Q4 2026 Q&A 3

Slide 4: BICO 2030 Strategy
BICO 2030 Strategy

Slide 5: From BICO 2.0 to The BICO 2030 Strategy
From BICO 2.0 to The BICO 2030 Strategy A three-step process that moved from business review to commercial plans and one group strategy. SPRING 2026 SUMMER 2026 AUTUMN 2026 Business review Commercial plans BICO 2030 Strategy 01 02 03 Comprehensive review The business review With input from the Produ

Slide 6: Precision Biology - In Total BICO is Serving a $10B TAM
Precision Biology - In Total BICO is Serving a $10B TAM Three growing markets; ~$1.5B serviceable today (SAM), growing ~4-7% p.a. 3D Biology & Biomaterials $2.7B TAM – low double-digit growth Shift from animal tests to human-relevant 3D models Cell Imaging, Isolation & CLD Automation of the Wet Lab

Slide 7: The Problem Worth Solving
The Problem Worth Solving 18,500 Recognized diseases to treat, but only 4,000 out of these have an FDA-approved THE NEED treatment = about 1 in 5 THE TOTAL R&D SPEND THE TIME INVESTED THE COST OF FAILING LATE $300B 10-15 years $2.7B Annual pharma R&D spend Bringing a drug to the market. In Average R

Slide 8: Where BICO Comes into Play
Where BICO Comes into Play 3-5 YEARS 10 YEARS Discovery Preclinical Phase I Phase II Phase III Approval Understand the disease Test in cell models, Safe in humans? Does it work in patients? Confirm at scale Regulatory review mechanism and identify organoids, 3D tissue models targets. Screen compound

Slide 9: Presenting BICO 2030 Strategy
Presenting BICO 2030 Strategy Accelerate Precision Biology BICO is the precision biology company. Each brand brings a specific capability for handling living material precisely, including the growth matrix, conditions, placement and analysis. Our lead market is cell-based applications in biotech and

Slide 10: BICO's Core Capabilities within Precision Biology
BICO’s Core Capabilities within Precision Biology A portfolio of instruments, software and biomaterials that supports more precise, reproducible and scalable biological work. HANDLING CULTURE ANALYSIS Preparing, moving and placing biological material. Creating and maintaining the conditions biology

Slide 11: Strategy and Value Creation in Brief
Strategy and Value Creation in Brief CORNERSTONE STRATEGIC FOCUS TO ACHIEVE BICO 2030 VALUE CREATION • Accelerate organic growth • Increase the share of consumables, services Precision Biology Concentrate resources on cell solutions and 3D cell models, and software in the revenue mix at the core whe

Slide 12: BICO's Financial Targets Remain Unchanged
BICO’s Financial Targets Remain Unchanged Reinforced focus on sustainable profit growth generation and long-term value creation. FINANCIAL TARGETS Double-digit organic growth >10% EBITDA margin less capitalized development cost Net debt / EBITDA <3.0x WHAT PERFORMANCE SHOWED WHAT BIOSERO TAUGHT US W

Slide 13: Executive Management aligned to BICO 2030
Executive Management aligned to BICO 2030 Anders Fogelberg Ewa Linsäter President & CEO CFO BICO is strengthening the Executive Management to improve business accountability and support customer- centric strategic execution. Julian Riba Petros Apostolopoulos Avijit Minocha CTO Managing Director Mana

Slide 14: Ownership. Innovation. Impact. This is BICO.
Ownership. Innovation. Impact. This is BICO. Ownership Innovation Impact We are empowered to take We are driven by curiosity, We are inspired by the ownership of our actions, guided by passion, and have the difference our work makes. decisions, and results. courage to explore new ideas. Through the

Slide 15: Invitation to Strategy Deep Dive on November 25
Invitation to Register at: Strategy www.bico.com/ Deep Dive on investors November 25

Slide 16: Group Performance Q3 2026
Group Performance Q3 2026

Slide 17: Summary Q3 2026
Summary Q3 2026 CASH FLOW FROM NET SALES ADJUSTED EBITDA OPERATING ACTIVITIES SEK 465m SEK 124m SEK -41m ORGANIC SALES ADJUSTED NWC/LTM SALES GROWTH EBITDA MARGIN 19% 27% 15% All numbers in this presentation refer to continuing operations unless otherwise stated. MatTek and Visikol have been classif

Slide 18: Sales Development LTM (SEKm)
Sales Development LTM (SEKm) SEKm • Sales SEK 465m, with organic growth 1,800 of 19% 1,600 • The extended SCIENION supply and 1,400 license agreements generated revenue of SEK 135m 1,200 • Strong benchtop instrument and 1,000 consumables sales 800 • Improved gross profit due to the 600 SCIENION agre

Slide 19: Adjusted EBITDA (SEKm) and Margin (%)
Adjusted EBITDA (SEKm) and Margin (%) SEKm % 140 30 124 • Adjusted EBITDA SEK 124m 120 27% 25 • EBITDA includes a significant 100 20 contribution from the SCIENION agreements 80 15 56 • Operating expenses continued to 60 13% decline, reflecting our continued 10 focus on cost discipline and 20 40 eff

Slide 20: Goodwill and Technology Impairment related to Biosero
Goodwill and Technology Impairment related to Biosero • BICO has reviewed its position in the large-scale integrated lab automation project business • Scale, capital, and proprietary robotics hardware- requirements for market leadership • Lab Automation remains an important market for our Precision

Slide 21: Cash Flow and Financial Position
Cash Flow and Financial Position • Cash flow from operating activities, SEK –41m • includes impact from changes in working capital of SEK –178m, mainly related to; • the license revenue recognized in the quarter converts to cash over the contract term • Decline in long-term lab automation projects •

Slide 22: Development in Net Working Capital between Q3 2025 and Q3 2026
Development in Net Working Capital between Q3 2025 and Q3 2026 SEKm % 800 30.0% 600 20.0% 400 15.4% 12.5% 12.6% WC Liabilities 10.4% 244 10.0% 200 195 Other Receivables 188 7.3% 156 Accounts Receivables 109 Inventories 0 0.0% Total NWC NWC / LTM Sales -200 -10.0% -400 -600 -20.0% Q3 25 Q4 25 Q1 26 Q

Slide 23: Focus Q4 2026
Focus Q4 2026

Slide 24: Focus Q4 2026
Focus Q4 2026 Host BICO 2030 strategy Deep dive on November 25 Anchor strategy internally and focus on top priorities for each Business Unit Assess options for Biosero to determine its ideal long-term potential Strengthen the Group’s capabilities within AI Ramp up for key launches 2027

Slide 25: Invitation to Strategy Deep Dive on November 25
Invitation to Register at: Strategy www.bico.com/ Deep Dive on investors November 25 25

Slide 26: Ownership. Innovation. Impact. This is BICO.
Ownership. Innovation. Impact. This is BICO. Ownership Innovation Impact We are empowered to take We are driven by curiosity, We are inspired by the ownership of our actions, guided by passion, and have the difference our work makes. decisions, and results. courage to explore new ideas. Through the

Slide 27: Q&A
Q&A

Slide 28: Financial Calendar
ANDERS FOGELBERG, PRESIDENT AND CEO EWA LINSÄTER, CFO BICO GROUP AB BICO GROUP AB Phone: EA Elisabeth Lindell, +46 761 73 40 59 Phone: +46 766 33 32 33 E-mail: elisabeth.lindell@bico.com E-mail: ewa.linsater@bico.com BICO strives towards the vision to enable life-science labs to accelerate the disco

Slide 29
Source: 6ix earnings call
More decks from BICO Group AB Class B
Q2 2026 Earnings Presentation24 slides · Aug 19, 2026
Q1 2026 Earnings Presentation31 slides · Apr 29, 2026
Q4 2025 Earnings Presentation40 slides · Feb 18, 2026
Q3 2025 Earnings Presentation36 slides · Nov 4, 2025
Q2 2025 Earnings Presentation26 slides · Aug 19, 2025
Q1 2025 Earnings Presentation27 slides · Apr 29, 2025